Tandem Diabetes Care Stock Today

TNDM Stock  USD 35.41  0.11  0.31%   

Performance

6 of 100

 
Low
 
High
Modest

Odds Of Distress

Less than 23

 
100  
 
Zero
Low
Tandem Diabetes is selling at 35.41 as of the 28th of March 2024; that is 0.31 percent up since the beginning of the trading day. The stock's lowest day price was 35.06. Tandem Diabetes has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Tandem Diabetes Care are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
14th of November 2013
Category
Healthcare
Classification
Health Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. The company has 65.63 M outstanding shares of which 8.08 M shares are at this time shorted by private and institutional investors with about 3.09 trading days to cover. More on Tandem Diabetes Care

Moving against Tandem Stock

  0.71MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.66MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.62TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr

Tandem Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Tandem Diabetes' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Tandem Diabetes or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorKim Blickenstaff
Thematic IdeaDrugs (View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Drugs, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Tandem Diabetes report their recommendations after researching Tandem Diabetes' financial statements, talking to executives and customers, or listening in on Tandem Diabetes' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Tandem Diabetes Care. The Tandem consensus assessment is calculated by taking the average forecast from all of the analysts covering Tandem Diabetes.
Financial Strength
Based on the key indicators related to Tandem Diabetes' liquidity, profitability, solvency, and operating efficiency, Tandem Diabetes Care is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of Tandem Diabetes Care is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.540.7849
Way Down
Slightly volatile
Total Current Liabilities205 M195.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total466 M443.8 M
Sufficiently Up
Slightly volatile
Total AssetsB952.7 M
Sufficiently Up
Slightly volatile
Total Current Assets785.4 M748 M
Sufficiently Up
Slightly volatile
Tandem Diabetes' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Tandem Diabetes' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tandem Diabetes' financial leverage. It provides some insight into what part of Tandem Diabetes' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Tandem Diabetes' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Tandem Diabetes deploys its capital and how much of that capital is borrowed.
Liquidity
Tandem Diabetes cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 415.67 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Tandem Diabetes Care has a current ratio of 4.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Tandem Diabetes until it has trouble settling it off, either with new capital or with free cash flow. So, Tandem Diabetes' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tandem Diabetes Care sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tandem to invest in growth at high rates of return. When we think about Tandem Diabetes' use of debt, we should always consider it together with cash and equity.

Other Cashflows From Financing Activities

(67,450)
Tandem Diabetes Care (TNDM) is traded on NASDAQ Exchange in USA. It is located in 12400 High Bluff Drive, San Diego, CA, United States, 92130 and employs 2,400 people. Tandem Diabetes is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tandem Diabetes's market, we take the total number of its shares issued and multiply it by Tandem Diabetes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Tandem Diabetes Care conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 65.63 M outstanding shares of which 8.08 M shares are at this time shorted by private and institutional investors with about 3.09 trading days to cover. Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47.
Check Tandem Diabetes Probability Of Bankruptcy
Ownership Allocation
Tandem Diabetes maintains a total of 65.63 Million outstanding shares. The majority of Tandem Diabetes Care outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tandem Diabetes to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tandem Diabetes Care. Please pay attention to any change in the institutional holdings of Tandem Diabetes Care as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Tandem Ownership Details

Tandem Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Tandem Diabetes jumping above the current price in 90 days from now is near 1%. The Tandem Diabetes Care probability density function shows the probability of Tandem Diabetes stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.6734. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Tandem Diabetes will likely underperform. Additionally, tandem Diabetes Care has an alpha of 0.0494, implying that it can generate a 0.0494 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 35.41HorizonTargetOdds Above 35.41
99.35%90 days
 35.41 
0.65%
Based on a normal probability distribution, the odds of Tandem Diabetes to move above the current price in 90 days from now is near 1 (This Tandem Diabetes Care probability density function shows the probability of Tandem Stock to fall within a particular range of prices over 90 days) .

Tandem Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Tandem Diabetes that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tandem Diabetes' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tandem Diabetes' value.
InstituionRecorded OnShares
Gw&k Investment Management, Llc2023-12-31
1.2 M
Capital Research & Mgmt Co - Division 32023-12-31
1.1 M
Paradice Investment Management Llc2023-12-31
1.1 M
Voloridge Investment Management, Llc2023-09-30
M
Geode Capital Management, Llc2023-12-31
M
Two Sigma Advisers, Llc2023-12-31
M
Stephens Inv Mgmt Group Llc2023-12-31
962.3 K
Morgan Stanley - Brokerage Accounts2023-12-31
872.2 K
Jacobs Levy Equity Management, Inc.2023-09-30
793.5 K
Blackrock Inc2023-12-31
9.2 M
Vanguard Group Inc2023-12-31
M
View Tandem Diabetes Diagnostics

Tandem Diabetes Historical Income Statement

Tandem Diabetes Care Income Statement is one of the three primary financial statements used for reporting Tandem's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Tandem Diabetes Care revenue and expense. Tandem Diabetes Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Tandem Diabetes' Gross Profit is very stable compared to the past year. As of the 28th of March 2024, Cost Of Revenue is likely to grow to about 399 M, while Interest Expense is likely to drop about 5.8 M. View More Fundamentals

Tandem Stock Against Markets

Picking the right benchmark for Tandem Diabetes stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Tandem Diabetes stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Tandem Diabetes is critical whether you are bullish or bearish towards Tandem Diabetes Care at a given time. Please also check how Tandem Diabetes' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Tandem Diabetes without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Tandem Diabetes Corporate Directors

Tandem Diabetes corporate directors refer to members of a Tandem Diabetes board of directors. The board of directors generally takes responsibility for the Tandem Diabetes' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Tandem Diabetes' board members must vote for the resolution. The Tandem Diabetes board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Rebecca RobertsonIndependent DirectorProfile
Douglas RoederIndependent DirectorProfile
Fred CohenIndependent DirectorProfile
Howard GreeneIndependent DirectorProfile

How to buy Tandem Stock?

Before investing in Tandem Diabetes, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Tandem Diabetes. To buy Tandem Diabetes stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Tandem Diabetes. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Tandem Diabetes stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Tandem Diabetes Care stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Tandem Diabetes Care stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Tandem Diabetes Care, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Tandem Stock please use our How to Invest in Tandem Diabetes guide.

Already Invested in Tandem Diabetes Care?

The danger of trading Tandem Diabetes Care is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Tandem Diabetes is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Tandem Diabetes. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Tandem Diabetes Care is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.43)
Revenue Per Share
11.509
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.